title: Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
abstract: An extremely rare subset of patients infected with HIV-1 designated as "non-progressing elite controllers" appears to be able to maintain stable CD4(+) T-cell counts and a median plasma viremia below the detection limit of current ultrasensitive assays (<50-80 copies/ml of plasma) for >10 years in the absence of antiretroviral therapy. Lymphocyte subsets (CD4(+), CD8(+)), immune activation markers (HLA-DR(+), CD38(+), Beta-2-microglobulin), and HIV-specific antibody responses were longitudinally examined in four non-progressing elite controllers over more than 5 years. Two control groups of seronegative healthy individuals and untreated patients infected with HIV-1 presenting detectable viremia were also included. None of the non-progressing elite controllers displayed the high T-cell activation levels generally seen in the seropositive individuals, keeping them within the normal range. Three non-progressing elite controllers showed no significant immune system abnormalities when compared to seronegative individuals, displaying a low proportion of HIV-1-specific binding antibodies and low avidity index, similar to those observed for individuals infected recently with HIV-1. One non-progressing elite controller exhibited CD8(+) T-cell counts and beta2-M levels above normal ranges and developed a low but "mature" (high-avidity) HIV-1-specific antibody response. Thus, the non-progressing elite controllers are able to maintain normal T-cell activation levels, which may contribute to prevent, or greatly reduce, the damage of the immune system typically induced by the HIV-1 over time. They are, however, immunologically heterogeneous and very low levels of antigen exposure seem to occur in these patients, sufficient for sustaining a low, but detectable, HIV-1-specific immunity.
authors.affiliation: Laboratório de AIDS & Imunologia Molecular, Instituto Oswaldo Cruz - FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Bello
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Velasco-de-Castro
authors.forename: Vera
authors.initials: V
authors.lastname: Bongertz
authors.forename: Caio A Santos
authors.initials: CA
authors.lastname: Rodrigues
authors.forename: Carmem B W
authors.initials: CB
authors.lastname: Giacoia-Gripp
authors.forename: Jose H
authors.initials: JH
authors.lastname: Pilotto
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Valdilea G
authors.initials: VG
authors.lastname: Veloso
authors.forename: Mariza G
authors.initials: MG
authors.lastname: Morgado
mesh_terms: D000328:Adult; D000915:Antibody Affinity; D000917:Antibody Formation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000276:immunology*; D020276:HIV Long-Term Survivors; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D015483:HIV Antibodies; D001613:beta 2-Microglobulin